Literature DB >> 23637280

Death receptor-ligand systems in cancer, cell death, and inflammation.

Henning Walczak1.   

Abstract

The discovery of tumor necrosis factor (TNF) marked the beginning of one of the most fascinating journeys in modern biomedical research. For the moment, this journey has culminated in the development of drugs that inhibit TNF. TNF blockers have revolutionized the treatment of many chronic inflammatory diseases. Yet, the journey seems far from over. TNF is the founding member of a family of cytokines with crucial functions in cell death, inflammation, and cancer. Some of these factors, most prominently TNF, CD95L, and TRAIL, can induce cell death. The receptors that mediate this signal are therefore referred to as death receptors, even though they also activate other signals. Here I will take you on a journey into the discovery and study of death receptor-ligand systems and how this inspired new concepts in cancer therapy and our current understanding of the interplay between cell death and inflammation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23637280      PMCID: PMC3632055          DOI: 10.1101/cshperspect.a008698

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  146 in total

1.  Fas engagement accelerates liver regeneration after partial hepatectomy.

Authors:  J Desbarats; M K Newell
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development.

Authors:  W C Yeh; A Itie; A J Elia; M Ng; H B Shu; A Wakeham; C Mirtsos; N Suzuki; M Bonnard; D V Goeddel; T W Mak
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

3.  Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo.

Authors:  Peiyee Lee; Masataka Sata; David J Lefer; Stephen M Factor; Kenneth Walsh; Richard N Kitsis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-10-31       Impact factor: 4.733

4.  Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.

Authors:  N Holler; R Zaru; O Micheau; M Thome; A Attinger; S Valitutti; J L Bodmer; P Schneider; B Seed; J Tschopp
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

5.  Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia.

Authors:  I Jeremias; C Kupatt; A Martin-Villalba; H Habazettl; J Schenkel; P Boekstegers; K M Debatin
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

6.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2.

Authors:  M R Sprick; M A Weigand; E Rieser; C T Rauch; P Juo; J Blenis; P H Krammer; H Walczak
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

7.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

Authors:  F C Kischkel; D A Lawrence; A Chuntharapai; P Schow; K J Kim; A Ashkenazi
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

8.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.

Authors:  Harald Ehrhardt; Simone Fulda; Irene Schmid; John Hiscott; Klaus-Michael Debatin; Irmela Jeremias
Journal:  Oncogene       Date:  2003-06-19       Impact factor: 9.867

Review 9.  Tumor necrosis factor signaling.

Authors:  H Wajant; K Pfizenmaier; P Scheurich
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

10.  Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8.

Authors:  Martin R Sprick; Eva Rieser; Heiko Stahl; Anne Grosse-Wilde; Markus A Weigand; Henning Walczak
Journal:  EMBO J       Date:  2002-09-02       Impact factor: 11.598

View more
  83 in total

Review 1.  Tissue-Resident Cytolytic Innate Lymphocytes in Cancer.

Authors:  Briana G Nixon; Ming O Li
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  Autophagy as a pro-death pathway.

Authors:  Donna Denton; Tianqi Xu; Sharad Kumar
Journal:  Immunol Cell Biol       Date:  2014-10-21       Impact factor: 5.126

Review 3.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

Review 4.  Thermoregulation as a disease tolerance defense strategy.

Authors:  Alexandria M Palaferri Schieber; Janelle S Ayres
Journal:  Pathog Dis       Date:  2016-11-03       Impact factor: 3.166

Review 5.  Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases.

Authors:  Junying Yuan; Palak Amin; Dimitry Ofengeim
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

6.  Interleukin-10 plays a key role in the modulation of neutrophils recruitment and lung inflammation during infection by Streptococcus pneumoniae.

Authors:  Hernán F Peñaloza; Pamela A Nieto; Natalia Muñoz-Durango; Francisco J Salazar-Echegarai; Javiera Torres; María J Parga; Manuel Alvarez-Lobos; Claudia A Riedel; Alexis M Kalergis; Susan M Bueno
Journal:  Immunology       Date:  2015-09       Impact factor: 7.397

7.  Cell-Extrinsic TNF Collaborates with TRIF Signaling To Promote Yersinia-Induced Apoptosis.

Authors:  Lance W Peterson; Naomi H Philip; Christopher P Dillon; John Bertin; Peter J Gough; Douglas R Green; Igor E Brodsky
Journal:  J Immunol       Date:  2016-10-12       Impact factor: 5.422

8.  Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL.

Authors:  Geun Taek Lee; Jeong Hyun Kim; Seok Joo Kwon; Mark N Stein; Jeong Hee Hong; Naoya Nagaya; Sachin Billakanti; Melina Minji Kim; Wun-Jae Kim; Isaac Yi Kim
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

9.  Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.

Authors:  Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Elisabet Cuyàs; Bruna Corominas-Faja; Esther Rodríguez-Gallego; Salvador Fernández-Arroyo; Begoña Martin-Castillo; Jorge Joven; Javier A Menendez
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

Review 10.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.